Jandus, Camilla

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2013 | 2012 | 2011 | 2010

2013

Démoulins, Thomas; Bassi, Isabelle; Thomann-Harwood, Lisa; Jandus, Camilla; Simon, Hans-Uwe; von Gunten, Stephan; Mc Cullogh, Kenneth C (2013). Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells. Nanomedicine-Nanotechnology Biology and Medicine, 9(6), pp. 806-817. Elsevier 10.1016/j.nano.2013.01.002

2012

Braun, Marion; Jandus, Camilla; Maurer, Patrik; Hammann-Haenni, Anya; Schwarz, Katrin; Bachmann, Martin F; Speiser, Daniel E; Romero, Pedro (2012). Virus-like particles induce robust human T-helper cell responses. European journal of immunology, 42(2), pp. 330-40. Weinheim: Wiley-VCH 10.1002/eji.201142064

Baumgaertner, Petra; Jandus, Camilla; Rivals, Jean-Paul; Derré, Laurent; Lövgren, Tanja; Baitsch, Lukas; Guillaume, Philippe; Luescher, Immanuel F; Berthod, Gregoire; Matter, Maurice; Rufer, Nathalie; Michielin, Olivier; Speiser, Daniel E (2012). Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. International journal of cancer, 130(11), pp. 2607-17. Malden, Mass.: Wiley-Blackwell 10.1002/ijc.26297

2011

Jandus, Camilla; Simon, Hans-Uwe; von Gunten, Stephan (2011). Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy. Biochemical pharmacology, 82(4), pp. 323-32. New York, N.Y.: Elsevier 10.1016/j.bcp.2011.05.018

2010

Derré, Laurent; Jandus, Camilla; Baumgaertner, Petra; Posevitz, Vilmos; Devêvre, Estelle; Romero, Pedro; Speiser, Daniel E (2010). Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. Methods in molecular biology, 626, pp. 231-249. Totowa, N.J.: Humana Press 10.1007/978-1-60761-585-9_16

Derré, Laurent; Rivals, Jean-Paul; Jandus, Camilla; Pastor, Sonia; Rimoldi, Donata; Romero, Pedro; Michielin, Olivier; Olive, Daniel; Speiser, Daniel E (2010). BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. Journal of clinical investigation, 120(1), pp. 157-67. Ann Arbor, Mich.: American Society for Clinical Investigation 10.1172/JCI40070

Provide Feedback